Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00183729
Status:
COMPLETED
Last Update Posted:
2018-01-17
First Post:
2005-09-14
Brief Title:
Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
Sponsor:
Eric Lenze
Organization:
University of Pittsburgh
Study Overview
Official Title:
Memantine for Enhancement of Rehabilitation Efficacy and Prevention of Major Depressive Disorder in Older Adults
Status:
COMPLETED
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or cardiopulmonary condition
Detailed Description:
Depression is a serious medical illness that is often difficult to diagnose and treat It occurs in people of all ages but is often overlooked in older adults Depression frequently co-occurs with other serious illnesses and may be mistaken by both patients and health care givers as a normal consequence of the illness However these misconceptions toward depression contribute to the underdiagnosis and undertreatment of depressive disorders in older people In turn depression may hinder a patients recovery from an illness This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or a cardiopulmonary condition
This double-blind study will last for 12 months Participants will be randomly assigned to receive either placebo or memantine which is a drug that is often used to treat Alzheimers disease Both memantine and placebo will be administered to participants for 12 weeks All participants will be followed for an additional 40 weeks Outcome measurements will include participants depressive symptoms motivation and learned helplessness In addition medication side effects functional outcome and incidence of major depressive disorder will be measured All measurements will be taken at Week 12 and Month 12
This double-blind study will last for 12 months Participants will be randomly assigned to receive either placebo or memantine which is a drug that is often used to treat Alzheimers disease Both memantine and placebo will be administered to participants for 12 weeks All participants will be followed for an additional 40 weeks Outcome measurements will include participants depressive symptoms motivation and learned helplessness In addition medication side effects functional outcome and incidence of major depressive disorder will be measured All measurements will be taken at Week 12 and Month 12
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| K23MH064196-02 | NIH | None | httpsreporternihgovquickSearchK23MH064196-02 |